Literature DB >> 29343147

Estimation of intra-arterial chemotherapy distribution to the retina in pediatric retinoblastoma patients using quantitative digital subtraction angiography.

Sravani Kondapavulur1, Daniel L Cooke1, Andrew Kao2, Matthew R Amans1, Matthew Alexander1, Robert Darflinger1, Christopher F Dowd1, Randall T Higashida1, Bertil Damato2, Van V Halbach1, Katherine K Matthay3, Steven W Hetts1.   

Abstract

Background and purpose The purpose of this article is to estimate the distribution of superselective intra-arterial chemotherapy (IAC) delivery to ocular target tissue using quantitative digital subtraction angiography (qDSA). Materials and methods From March 2010 to January 2016, 50 ophthalmic artery contrast DSAs obtained immediately prior to IAC infusions in 22 patients were analyzed. This study was conducted under a retrospective review IRB (no. 10-01862). Parametric color-coded DSAs (iFlow, Siemens Medical) were post-processed (MATLAB, The Mathworks Inc.) using two methods: two box regions of interest (pre-retina and globe) and four custom regions of interest (ROIs-ophthalmic artery, choroid, supraclinoid internal carotid artery (ICA), cavernous ICA). Mean interobserver reliability of custom ROI selection is presented as a 95% confidence interval of interclass correlation, and fractional chemotherapy delivery to selected ROIs as means ± standard deviation in this study. Results The estimated fraction of chemotherapy delivered to the globe with the first method was 79.5%. Percentage regional delivery using the second method was as follows: ophthalmic artery, 85.8%; choroid, 60.5%; supraclinoid ICA, 14.2%. The cavernous ICA ROI (encompassing distal catheter and potential reflux) gave a signal equivalent to 9.3% of total delivery. Conclusion Parametric color-coded qDSA can estimate the fraction of IAC delivered to the retina and other orbital structures in ocular retinoblastoma patients. This information can inform delivery location and dosing strategies on a patient-specific basis.

Entities:  

Keywords:  DSA technique development; interventional neuro-oncology; intra-arterial chemotherapy

Mesh:

Substances:

Year:  2018        PMID: 29343147      PMCID: PMC5847018          DOI: 10.1177/1591019917749825

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  13 in total

Review 1.  Intra-arterial chemotherapy for retinoblastoma: the beginning of a long journey.

Authors:  Carol L Shields; Jerry A Shields
Journal:  Clin Exp Ophthalmol       Date:  2010-03-25       Impact factor: 4.207

2.  Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery.

Authors:  Y P Gobin; T F Cloughesy; K L Chow; G R Duckwiler; J W Sayre; K Milanese; F Viñuela
Journal:  Radiology       Date:  2001-03       Impact factor: 11.105

3.  Retinoblastoma: diagnosis and management.

Authors:  D H Abramson
Journal:  CA Cancer J Clin       Date:  1982 May-Jun       Impact factor: 508.702

4.  Radiation dose reduction in intra-arterial chemotherapy infusion for intraocular retinoblastoma.

Authors:  Daniel L Cooke; Charles E Stout; Warren T Kim; Steven W Hetts; Randall T Higashida; Van V Halbach; Christopher F Dowd; Robert G Gould
Journal:  J Neurointerv Surg       Date:  2014-01-02       Impact factor: 5.836

5.  The modern role of radiation therapy in treating advanced-stage retinoblastoma: long-term outcomes and racial differences.

Authors:  Amber Orman; Tulay Koru-Sengul; Feng Miao; Arnold Markoe; Joseph E Panoff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-13       Impact factor: 7.038

Review 6.  Retinoblastoma.

Authors:  Helen Dimaras; Kahaki Kimani; Elizabeth A O Dimba; Peggy Gronsdahl; Abby White; Helen S L Chan; Brenda L Gallie
Journal:  Lancet       Date:  2012-03-12       Impact factor: 79.321

7.  Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience.

Authors:  Y Pierre Gobin; Ira J Dunkel; Brian P Marr; Scott E Brodie; David H Abramson
Journal:  Arch Ophthalmol       Date:  2011-02-14

8.  Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma.

Authors:  Lejla Mutapcic Vajzovic; Timothy G Murray; Mohammad A Aziz-Sultan; Amy C Schefler; Stacey Quintero Wolfe; Ditte Hess; Cristina E Fernandes; Sander R Dubovy
Journal:  Clin Ophthalmol       Date:  2011-02-10

9.  Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution.

Authors:  Sheila Thampi; Steven W Hetts; Daniel L Cooke; Paul J Stewart; Elizabeth Robbins; Anuradha Banerjee; Steven G Dubois; Devron Char; Van Halbach; Katherine Matthay
Journal:  Clin Ophthalmol       Date:  2013-05-27

10.  Novel Software-Assisted Hemodynamic Evaluation of Pelvic Flow During Chemoperfusion of Pelvic Arteries for Bladder Cancer: Double- Versus Single-Balloon Technique.

Authors:  Kiyohito Yamamoto; Kazuhiro Yamamoto; Go Nakai; Haruhito Azuma; Yoshifumi Narumi
Journal:  Cardiovasc Intervent Radiol       Date:  2016-01-27       Impact factor: 2.740

View more
  3 in total

1.  Effectiveness of alternative routes of intra-arterial chemotherapy administration for retinoblastoma: Potential for response and complications.

Authors:  Coridon Quinn; Ramachandra Tummala; Jill Anderson; Tambra Dahlheimer; David Nascene; Bharathi Jagadeesan
Journal:  Interv Neuroradiol       Date:  2019-03-31       Impact factor: 1.610

2.  Severe Periocular Edema after Intraarterial Carboplatin Chemotherapy for Retinoblastoma in a Rabbit (Oryctolagus cuniculus) Model.

Authors:  Tai L Oatess; Patty H Chen; Anthony B Daniels; Lauren E Himmel
Journal:  Comp Med       Date:  2020-03-11       Impact factor: 0.982

3.  Quantitative color-coded digital subtraction neuroangiography for pediatric arteriovenous shunting lesions.

Authors:  Grace M Y Ma; Adam A Dmytriw; Premal A Patel; Nicholas Shkumat; Timo Krings; Manohar M Shroff; Prakash Muthusami
Journal:  Childs Nerv Syst       Date:  2019-07-06       Impact factor: 1.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.